SynAgile is developing DopaFuse, designed to be the first patient-friendly, noninvasive therapy for continuous delivery of L-DOPA and carbidopa. The medication is delivered from a small, comfortable device worn in the mouth.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/synagile” connections=”true” suffix=””]
SynAgile uses its proprietary OraFuse_ intraoral technology platform, to develops and commercializes drug delivery systems. Based on it DopaFuse_, the first therapy to continuously and noninvasively deliver L-DOPA and carbidopa is developed. DopaFuse_ contains a novel, highly concentrated formulation that enables a daily dose of L-DOPA and carbidopa to be delivered in a small volume.
In Aug 2017, SynAgile Corporation received $10.4Mn funding in equity investment led by affiliates of TAMCAP LLC. The proceeds will be used to conduct the first-in-human, Phase 2 clinical trial of SynAgiles DopaFuse_ delivery system.